Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Response Biomed Corp RPBIF

"Response Biomedical Corp is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets."


GREY:RPBIF - Post by User

Bullboard Posts
Comment by dimar66on Jan 11, 2009 2:24am
277 Views
Post# 15696933

RE: RE: RE: Interesting Article

RE: RE: RE: Interesting ArticleNanogen may have a really good test after two years of development, but it appears to be more of a clinical laboratory thing than an easy to use POC (point of care).  In any case we know something about  how fast development work goes, been there done that.

expected to be conducted in less than half the time it takes to runcurrent molecular tests. But how quick is that?

By 2010, the worldwideinfluenza diagnostics market is likely to reach $200 million.
RBM is already gaining market share, we will grow into this market.

~~dimar
Bullboard Posts